The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How could new immunotherapy treatments in acute myeloid leukemia change current practice?
Amir Fathi
September 24, 2021
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, KNOW AML spoke to Amir Fathi, Massachusetts General Hospital, Boston, US. We Asked, How could new immunotherapy treatments in acute myeloid leukemia change current practice? Fathi begins by discussing immunotherapeutic gemtuzumab and its practical application. He goes on to outline emerging drugs and the molecular targets for these immunotherapies such as flotetuzumab, for patients with relapsed/refractory or early stage acute myeloid leukemia. Finally, Fathi discusses interesting molecular targets such as CD47, p53 and CD70 and their potential treatment routes.
